Compare IREN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IREN | HALO |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 12.0B |
| IPO Year | 2021 | 2001 |
| Metric | IREN | HALO |
|---|---|---|
| Price | $25.17 | $124.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 9 |
| Target Price | $77.81 | ★ $108.78 |
| AVG Volume (30 Days) | ★ 39.3M | 2.1M |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 3.11 |
| Revenue | ★ $707,007,000.00 | $151,862,000.00 |
| Revenue This Year | $297.12 | $34.69 |
| Revenue Next Year | $163.96 | $11.65 |
| P/E Ratio | ★ N/A | $40.28 |
| Revenue Growth | ★ 41.11 | N/A |
| 52 Week Low | $25.59 | $61.23 |
| 52 Week High | $76.87 | $125.43 |
| Indicator | IREN | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 25.08 | 71.60 |
| Support Level | N/A | $105.27 |
| Resistance Level | $44.21 | N/A |
| Average True Range (ATR) | 2.32 | 3.48 |
| MACD | -1.13 | 1.13 |
| Stochastic Oscillator | 2.31 | 93.48 |
IREN owns data centers powered by renewable energy in Canada and the US for bitcoin mining and AI cloud infrastructure. The company is in the process of converting its existing bitcoin capacity for AI purposes and securing new power and land supply to expand its data center operation. IREN works closely with industry leaders in AI, such as Microsoft, to support their cloud infrastructure ambitions.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.